A clinical study to assess the effect of the mixture of recombinant human platelet derived growth factor (rhPDGF) and Beta tri calcium phosphate (β- TCP) in the treatment of periodontal intrabony defects.
- Conditions
- Health Condition 1: null- Periodontitis
- Registration Number
- CTRI/2017/11/010554
- Lead Sponsor
- Dr KAVYAMALA DUBBA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
1.Age: 20-60 years
2.Presence of at least one tooth on each side of the mouth with probing depth (PD) and clinical attachment loss (CAL) >= 5mm.
3.Radiographic evidence of interproximal intraosseous defect depth>=3mm.
1.Poor oral hygiene and poor patient compliance.
2.Smokers.
3.Pregnant and lactating women.
4.Patients with the study tooth exhibiting grade III mobility.
5.Patients with study tooth exhibiting furcation involvement of grade II or more.
6.Patients with any systemic diseases that contraindicate periodontal treatment
7.Patients with history of drug intake known to affect the periodontium i.e., systemic antibiotics and long term anti-inflammatory drugs during the last 6 months.
8.Patients with unmanageable occlusal dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Amount and percentage of radiographic bone fill in the periodontal intraosseous defectTimepoint: 6months <br/ ><br>
- Secondary Outcome Measures
Name Time Method Changes in probing depth. <br/ ><br>Changes in clinical attachment level. <br/ ><br>Amount of bone fill. <br/ ><br>Gingival recession. <br/ ><br>Timepoint: 3 and 6 months <br/ ><br>